{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:11:44Z","timestamp":1792087904397,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41591-019-0474-7","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T12:03:12Z","timestamp":1559822592000},"page":"929-935","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":219,"title":["Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevive","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1230-7117","authenticated-orcid":false,"given":"Matthew J.","family":"Wongchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiMeng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Ballinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"key":"474_CR1","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"key":"474_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358\u2013365 (2012).","journal-title":"Lancet"},{"key":"474_CR3","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867\u20131876 (2014).","journal-title":"N. Engl. J. Med."},{"key":"474_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30\u201339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"474_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long, G. V. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444\u2013451 (2015).","journal-title":"Lancet"},{"key":"474_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"474_CR7","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"474_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375\u2013384 (2015).","journal-title":"Lancet Oncol."},{"key":"474_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"474_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1084\/jem.20051848","volume":"203","author":"H Sumimoto","year":"2006","unstructured":"Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF\u2013MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651\u20131656 (2006).","journal-title":"J. Exp. Med."},{"key":"474_CR11","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","volume":"18","author":"JS Khalili","year":"2012","unstructured":"Khalili, J. S. et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 melanoma. Clin. Cancer Res. 18, 5329\u20135340 (2012).","journal-title":"Clin. Cancer Res."},{"key":"474_CR12","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","volume":"19","author":"DT Frederick","year":"2013","unstructured":"Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225\u20131231 (2013).","journal-title":"Clin. Cancer Res."},{"key":"474_CR13","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","volume":"18","author":"JS Wilmott","year":"2012","unstructured":"Wilmott, J. S. et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386\u20131394 (2012).","journal-title":"Clin. Cancer Res."},{"key":"474_CR14","doi-asserted-by":"publisher","first-page":"e25218","DOI":"10.4161\/onci.25218","volume":"2","author":"B Schilling","year":"2013","unstructured":"Schilling, B. & Paschen, A. Immunological consequences of selective BRAF inhibitors in malignant melanoma: neutralization of myeloid-derived suppressor cells. Oncoimmunology 2, e25218 (2013).","journal-title":"Oncoimmunology"},{"key":"474_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/pcmr.12098","volume":"26","author":"GV Long","year":"2013","unstructured":"Long, G. V. et al. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell Melanoma Res. 26, 499\u2013508 (2013).","journal-title":"Pigment Cell Melanoma Res."},{"key":"474_CR16","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","volume":"70","author":"A Boni","year":"2010","unstructured":"Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213\u20135219 (2010).","journal-title":"Cancer Res."},{"key":"474_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1541-7786.MCR-06-0077","volume":"4","author":"M Kono","year":"2006","unstructured":"Kono, M. et al. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol. Cancer Res. 4, 779\u2013792 (2006).","journal-title":"Mol. Cancer Res."},{"key":"474_CR18","doi-asserted-by":"publisher","first-page":"e22890","DOI":"10.4161\/onci.22890","volume":"2","author":"B Sapkota","year":"2013","unstructured":"Sapkota, B., Hill, C. E. & Pollack, B. P. Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology 2, e22890 (2013).","journal-title":"Oncoimmunology"},{"key":"474_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0181","volume":"2","author":"LJ Vella","year":"2014","unstructured":"Vella, L. J. et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol. Res. 2, 351\u2013360 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"474_CR20","doi-asserted-by":"publisher","first-page":"e26615","DOI":"10.4161\/onci.26615","volume":"2","author":"ZA Cooper","year":"2013","unstructured":"Cooper, Z. A. et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2, e26615 (2013).","journal-title":"Oncoimmunology"},{"key":"474_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012).","journal-title":"J. Transl. Med."},{"key":"474_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954 (2002).","journal-title":"Nature"},{"key":"474_CR23","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin, J. A. et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135\u20132147 (2005).","journal-title":"N. Engl. J. Med."},{"key":"474_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan, P. T. et al. Mechanism of activation of the RAF\u2013ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855\u2013867 (2004).","journal-title":"Cell"},{"key":"474_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"P Ascierto","year":"2016","unstructured":"Ascierto, P. et al. Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17, 1248\u20131260 (2016).","journal-title":"Lancet Oncol."},{"key":"474_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"474_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"474_CR28","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"474_CR29","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018\u20132028 (2015).","journal-title":"N. Engl. J. Med."},{"key":"474_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","volume":"44","author":"PJR Ebert","year":"2016","unstructured":"Ebert, P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609\u2013621 (2016).","journal-title":"Immunity"},{"key":"474_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","volume":"2","author":"ZA Cooper","year":"2014","unstructured":"Cooper, Z. A. et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2, 643\u2013654 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"474_CR32","doi-asserted-by":"publisher","first-page":"279ra241","DOI":"10.1126\/scitranslmed.aaa4691","volume":"7","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan, S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7, 279ra241\u2013279ra241 (2015).","journal-title":"Sci. Transl. Med."},{"key":"474_CR33","first-page":"778","volume":"28","author":"O Hamid","year":"2015","unstructured":"Hamid, O. et al. Preliminary clinical safety, tolerability and activity of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600 metastatic melanoma. Pigment Cell Melanoma Res. 28, 778 (2015).","journal-title":"Pigment Cell Melanoma Res."},{"key":"474_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12967-016-0763-6","volume":"14","author":"R Sullivan","year":"2016","unstructured":"Sullivan, R. et al. Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (antiPDL1) combined with vemurafenib in BRAFV600 mutant metastatic melanoma. J. Transl. Med. 14, 9\u201310 (2016).","journal-title":"J. Transl. Med."},{"key":"474_CR35","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.1200\/JCO.2018.36.15_suppl.9559","volume":"36","author":"S Rapisuwon","year":"2018","unstructured":"Rapisuwon, S. et al. Analysis of the kinetics and effects of vemurafenib (V) plus cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): implications for combination with immunotherapy. J. Clin. Oncol. 36, 9559\u20139559 (2018).","journal-title":"J. Clin. Oncol."},{"key":"474_CR36","doi-asserted-by":"publisher","first-page":"v428","DOI":"10.1093\/annonc\/mdx377.003","volume":"28","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma. Ann. Oncol. 28, v428\u2013v448 (2017).","journal-title":"Ann. Oncol."},{"key":"474_CR37","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/S0959-8049(17)30482-3","volume":"72","author":"GV Long","year":"2017","unstructured":"Long, G. V. et al. Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. Eur. J. Cancer 72, S122\u2013S123 (2017).","journal-title":"Eur. J. Cancer"},{"key":"474_CR38","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long, G. V. et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 17, 1743\u20131754 (2016).","journal-title":"Lancet Oncol."},{"key":"474_CR39","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud, A. I. et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102\u20134109 (2016).","journal-title":"J. Clin. Oncol."},{"key":"474_CR40","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-17-0172","volume":"23","author":"MJ Wongchenko","year":"2017","unstructured":"Wongchenko, M. J. et al. Gene expression profiling in BRAF-mutated melanoma reveals patient subgroups with poor outcomes to vemurafenib that may be overcome by cobimetinib plus vemurafenib. Clin. Cancer Res. 23, 5238\u20135245 (2017).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0474-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0474-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0474-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:59:32Z","timestamp":1684605572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-019-0474-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1038\/s41591-019-0474-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by F. Hoffman-La Roche Ltd. R.J.S. reports personal fees from Amgen, Merck, Genentech, Array and Novartis; research grants from Amgen and Merck; and clinical trial support from Merck, Genentech and Novartis during the conduct of the study; and by personal fees from Compugen, Replimune and Syndax outside the submitted work. O.H. reports advisory board fees from Roche and speaker bureau fees from Genentech during the conduct of the study; advisory board fees from Amgen, Novartis and Bristol-Myers Squibb; speaker bureau fees from Amgen, Bristol-Myers Squibb, Novartis and Array Biopharma; and research support paid to institution from AstraZeneca, Bristol-Myers Squibb, Celldex, Genentech, Immunocore, Merck Serono, MedImmune, Novartis, Pfizer, Rinat and Roche outside the submitted work. R.G. reports personal fees and grants from Roche\/Genentech during the conduct of the study, personal fees and grants from Bristol-Myers Squibb and Novartis; and grants from Merck and Array Biopharma outside the submitted work. J.R.I. reports consultancy fees from BioMed Valley and Armo Biosciences and employment with Janssen Pharmaceuticals outside the submitted work. M.R.P. reports no competing interests. F.S.H. reports clinical trial support paid to institution from Genentech during the conduct of the study; consultancy fees from Genentech, Merck, Novartis, Bristol-Myers Squibb, Aduro, Partner Therapeutics, EMD Serono, Sanofi and Celldex; advisory board fees from Apricity; and research grants paid to institution from Bristol-Myers Squibb outside the submitted work; F.S.H. also reports an issued patent for Therapeutic Peptides and pending patents for MICA Related Disorders and Angiopoietin-2 as Therapeutic Target for Cancer. K.D.L. reports grants from Roche\/Genentech during the conduct of the study and consultancy fees from Roche\/Genentech outside the submitted work. H.A.T. reports grants and personal fees from Roche\/Genentech during the conduct of the study; and grants and personal fees from Bristol-Myers Squibb, Merck and Novartis outside the submitted work. G.H. reports employment with Roche. M.J.W. reports employment and stock ownership with Genentech\/Roche and stock ownership with ARIAD Pharmaceuticals. Y.C. reports employment with Genentech\/Roche. L.R. reports employment with Genentech\/Roche. M.B. reports employment and stock ownership with Genentech\/Roche. Y.Y. reports employment with Genentech\/Roche and stock ownership with Genentech\/Roche. E.C. reports employment and stock ownership with Genentech\/Roche. P.H. reports consultancy and advisory fees from Dragonfly, GlaxoSmithKline, Immatics and Sanofi outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}